AU2020397173A1 - Use of a KV7 potassium channel opener for treating pain - Google Patents

Use of a KV7 potassium channel opener for treating pain Download PDF

Info

Publication number
AU2020397173A1
AU2020397173A1 AU2020397173A AU2020397173A AU2020397173A1 AU 2020397173 A1 AU2020397173 A1 AU 2020397173A1 AU 2020397173 A AU2020397173 A AU 2020397173A AU 2020397173 A AU2020397173 A AU 2020397173A AU 2020397173 A1 AU2020397173 A1 AU 2020397173A1
Authority
AU
Australia
Prior art keywords
pain
compound
human
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020397173A
Other languages
English (en)
Inventor
Gregory N. Beatch
James Philip Johnson Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of AU2020397173A1 publication Critical patent/AU2020397173A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Light Guides In General And Applications Therefor (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
AU2020397173A 2019-12-06 2020-12-04 Use of a KV7 potassium channel opener for treating pain Pending AU2020397173A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962945093P 2019-12-06 2019-12-06
US62/945,093 2019-12-06
US201962948010P 2019-12-13 2019-12-13
US62/948,010 2019-12-13
PCT/US2020/063471 WO2021113757A1 (en) 2019-12-06 2020-12-04 Use of a kv7 potassium channel opener for treating pain

Publications (1)

Publication Number Publication Date
AU2020397173A1 true AU2020397173A1 (en) 2022-06-23

Family

ID=73856375

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020397173A Pending AU2020397173A1 (en) 2019-12-06 2020-12-04 Use of a KV7 potassium channel opener for treating pain

Country Status (14)

Country Link
EP (1) EP4069211A1 (https=)
JP (1) JP2023504166A (https=)
KR (1) KR20220113411A (https=)
CN (1) CN114786658A (https=)
AU (1) AU2020397173A1 (https=)
BR (1) BR112022010733A2 (https=)
CA (1) CA3159436A1 (https=)
CL (1) CL2022001477A1 (https=)
CR (1) CR20220318A (https=)
IL (1) IL293504A (https=)
MX (1) MX2022006877A (https=)
PE (1) PE20221169A1 (https=)
TW (1) TW202133847A (https=)
WO (1) WO2021113757A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511220B (zh) 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
CA3151863C (en) * 2021-10-27 2024-01-02 Shanghai Zhimeng Biopharma, Inc. Compound as potassium channel regulator and preparation and use thereof
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US7553858B2 (en) * 2003-12-17 2009-06-30 Meda Pharma Gmbh & Co. Kg Combination of flupirtine and tramadol
SG174095A1 (en) * 2006-08-23 2011-09-29 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US9248122B2 (en) * 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
WO2019217924A1 (en) * 2018-05-11 2019-11-14 Xenon Pharmaceuticals Inc. Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener

Also Published As

Publication number Publication date
CA3159436A1 (en) 2021-06-10
BR112022010733A2 (pt) 2022-08-23
TW202133847A (zh) 2021-09-16
WO2021113757A1 (en) 2021-06-10
CN114786658A (zh) 2022-07-22
JP2023504166A (ja) 2023-02-01
CR20220318A (es) 2022-10-07
KR20220113411A (ko) 2022-08-12
MX2022006877A (es) 2022-07-11
IL293504A (en) 2022-08-01
PE20221169A1 (es) 2022-07-25
CL2022001477A1 (es) 2023-04-28
EP4069211A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
US6248789B1 (en) Administration of ketamine to manage pain and to reduce drug dependency
US9119848B2 (en) Morphinan derivatives for the treatment of drug overdose
US20240342156A1 (en) Methods for treating pain
US6538008B1 (en) Combination of a selective NMDA NR2B antagonist and an opioid analgesic
CA2230690C (en) Administration of ketamine to manage pain and to reduce drug dependency
TW200418474A (en) Method of treating post-operative nausea and vomiting
AU2020397173A1 (en) Use of a KV7 potassium channel opener for treating pain
WO2009145289A1 (ja) 鎮痛耐性抑制剤
JP2017506244A (ja) ノルイボガイン及び関連化合物を用いた治療方法
CA2688542C (en) Methods and compositions for administration of oxybutynin
US20160095830A1 (en) Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain
JPS62298530A (ja) 坐薬用医薬組成物
NO309965B1 (no) Oralt farmasøytisk antihostepreparat
WO2025064708A1 (en) Compositions comprising oxytocin and methods of treating opioid overdose
KR20040020054A (ko) 통증 치료시 중독 예방
US10736874B1 (en) Methods for treating pain associated with sickle cell disease
US20080132531A1 (en) Synergistic combinations of norketamine and opioid analgesics
EP1734940B1 (en) Combinations of deramciclane and opioids for use as analgesics
HK40080562A (en) Use of a kv7 potassium channel opener for treating pain
AU2004233582B2 (en) Pharmaceutical compositon comprising a cathepsin S inhibitor and an opioid
MILLS et al. Opioid Side Effects
EP1797883A2 (en) Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
US20090281194A1 (en) Combinations for treating HIV-associated pain